Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553642 · ClinicalTrials.gov registry record · Phase 2
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
A Phase 2 study of Melanoma and Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 5
- Study locations
NCT02553642 is a Phase 2 study of Melanoma and Bladder Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 81 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02553642, a Phase 2 study of Melanoma and Bladder Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Nivolumab plus Ipilimumab
Study Locations (5)
New York
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- University of Connecticut Health Center - Farmington
New Jersey
- Memorial Sloan Kettering Monmouth - Middletown
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553642
The ClinicalTrials.gov registry entry for NCT02553642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (89% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02553642 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02553642 about?
NCT02553642 is a clinical study titled "Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)". The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
What is the current status of trial NCT02553642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-09-14. Estimated completion is 2024-04-29.
What conditions does trial NCT02553642 study?
This clinical trial studies the following conditions: Melanoma, Bladder Cancer.
What interventions are being tested in trial NCT02553642?
The interventions under investigation include: Nivolumab (DRUG), Nivolumab plus Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02553642?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02553642 being conducted?
This trial has 5 study locations across Connecticut, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.